



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

AUG 31 2004

Re: Reyataz
Docket No.: 04E-0023

The Honorable Jon Dudas
Acting Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Acting Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 5,849,911, filed by Novartis Corporation, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Reyataz, the human drug product claimed by the patent.

The total length of the regulatory review period for Reyataz is 1,723 days. Of this time, 1,540 days occurred during the testing phase and 183 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: October 3, 1998.

The applicant claims October 2, 1998, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was October 3, 1998, which was thirty days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: December 20, 2002.

FDA has verified the applicant's claim that the new drug application (NDA) for Reyataz (NDA 21-567) was initially submitted on December 20, 2002.

3. The date the application was approved: June 20, 2003.

FDA has verified the applicant's claim that NDA 21-567 was approved on June 20, 2003.


04E-0023

LET 4

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jane A. Axelrad". The signature is fluid and cursive, with the first name "Jane" and last name "Axelrad" clearly legible.

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Samuel J. DuBoff
Bristol Myers Squibb Company
Patent Counsel
5 Research Parkway, P.O. Box 5100
Wallingford, CT 06492-7660